

## **DECLARATION OF INTERESTS**

A.C. and J.P.L. are named on a patent pending for the combined use of retigabine (ezogabine) and ketamine to amplify antidepressant effects to treat depression and related conditions. F.J.T. reports receiving consulting fees from Roche Diagnostics GmbH and Cellarity Inc. and ownership interest in Cellarity, Inc. and Dermagnostix. All other authors declare no competing interests.

Received: July 27, 2021

Revised: March 1, 2022

Accepted: May 2, 2022

Published: May 31, 2022